BRD5529

BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) [1][2].

Product Specifications

CAS Number

[1358488-78-4]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

E1/E2/E3 Enzyme

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/brd5529.html

Purity

98.94

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(NC(C2=CC=C(C)C=C2)=O)=CN=C1N3CCC(N4CCCCC4)(C(N)=O)CC3)O

Molecular Formula

C25H31N5O4

Molecular Weight

465.54

Precautions

H315, H319, H335

References & Citations

[1]Leshchiner ES, et al. Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatorybowel disease. Proc Natl Acad Sci U S A. 2017 Oct 24;114 (43) :11392-11397.|[2]Theodore J Kottom, et al. Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9. Drugs R D. 2022 Jun;22 (2) :165-173.